Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Expands bioprocessing footprint across Asia
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
76 of 180 long COVID-associated genes also linked to ME
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Subscribe To Our Newsletter & Stay Updated
